CT-388: A Weekly Signal-Biased GLP-1/GIP Drug Shows Strong Weight Loss in Preclinical and Early Human Data
CT-388, a once-weekly signal-biased dual GLP-1/GIP agonist, achieved greater weight loss than unbiased agonism in preclinical models, with early human data supporting translation to clinical settings.
Quick Facts
What This Study Found
Signal-biased dual GLP-1/GIP receptor agonism with CT-388 produced superior weight loss compared to unbiased agonism in preclinical models, with supportive early clinical data in obesity.
Key Numbers
How They Did This
Combined preclinical (cell-based assays and animal models) and early clinical study in participants with obesity evaluating CT-388 efficacy.
Why This Research Matters
If biased signaling truly delivers better weight loss outcomes, CT-388 could outperform current dual-agonist drugs like tirzepatide, raising the bar for obesity pharmacotherapy.
The Bigger Picture
The concept of biased agonism — activating one signaling pathway over others — could revolutionize how peptide drugs are designed, creating more effective medicines with fewer side effects across many disease areas.
What This Study Doesn't Tell Us
Very early clinical data (likely phase 1); preclinical advantages don't always translate to humans; long-term safety profile unknown.
Questions This Raises
- ?Will CT-388's signal bias advantage hold up in larger phase 2/3 trials?
- ?Does biased agonism reduce GI side effects compared to unbiased dual agonists?
Trust & Context
- Key Stat:
- Biased > unbiased agonism Signal-biased dual agonism produced greater weight loss than traditional approaches in preclinical models
- Evidence Grade:
- Combined preclinical and early clinical data — promising but very preliminary for human efficacy conclusions.
- Study Age:
- Published in 2026, at the forefront of biased agonism drug development for obesity.
- Original Title:
- Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.
- Published In:
- Molecular metabolism, 103, 102291 (2026)
- Authors:
- Chakravarthy, Manu V(2), Rodriguez, Ruben, Hergarden, Anne, Elliott, Michael A, Frias, Juan P, Argüelles-Tello, Federico A, Tenorio, Edgar, Rankin, Jonathan E, Wu, Jingtao, Krishnan, Shyam, Erlanson, Daniel A, Fucini, Raymond V, Bone, Derek, Iwig, Jeffrey S, Acosta, Luis, Untereiner, Ashley, Pant, Asmita, Patton, Avalon, Sanchez-Sanchez, Leyla L, Luo, Jian, Steinberg, Alexandra, Bialonczyk, Damian, Hansen, Stig K
- Database ID:
- RPEP-14954
Evidence Hierarchy
Frequently Asked Questions
What is signal-biased agonism?
Traditional drugs activate all signaling pathways at a receptor equally. Signal-biased drugs preferentially activate one pathway (like cAMP) over others, which can increase desired effects while reducing unwanted ones.
How does CT-388 compare to tirzepatide?
Both target GLP-1 and GIP receptors, but CT-388 uses biased signaling that may produce better weight loss. Direct comparison trials haven't been done yet.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14954APA
Chakravarthy, Manu V; Rodriguez, Ruben; Hergarden, Anne; Elliott, Michael A; Frias, Juan P; Argüelles-Tello, Federico A; Tenorio, Edgar; Rankin, Jonathan E; Wu, Jingtao; Krishnan, Shyam; Erlanson, Daniel A; Fucini, Raymond V; Bone, Derek; Iwig, Jeffrey S; Acosta, Luis; Untereiner, Ashley; Pant, Asmita; Patton, Avalon; Sanchez-Sanchez, Leyla L; Luo, Jian; Steinberg, Alexandra; Bialonczyk, Damian; Hansen, Stig K. (2026). Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.. Molecular metabolism, 103, 102291. https://doi.org/10.1016/j.molmet.2025.102291
MLA
Chakravarthy, Manu V, et al. "Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.." Molecular metabolism, 2026. https://doi.org/10.1016/j.molmet.2025.102291
RethinkPeptides
RethinkPeptides Research Database. "Effects of CT-388, a once-weekly signaling-biased dual GLP-1..." RPEP-14954. Retrieved from https://rethinkpeptides.com/research/chakravarthy-2026-effects-of-ct388-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.